RxDoctor Payments DataLook up a doctor →

Raul Torres-Heisecke, MD

Clinical Cardiac Electrophysiology · Tyler, TXNPI 1952518813

Payments from drug & device makers

$700,719in general payments, 2019–2025

Across 534 payments — averaging $1312.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$310K
  • Medtronic$216K
  • Cvrx, Inc.$167K
  • Abbott$4K
  • Novartis$1K
  • Boston Scientific$1K
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$5,55642%
  • Food & beverage$7,76458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$700,719 in reported general payments places this provider in the 90th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$225,857
Medicare patients
777
Services billed
3,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban632$564,769
XareltoRivaroxaban172$170,793
JardianceEmpagliflozin123$104,070
MultaqDronedarone Hcl50$74,597
Dofetilide182$23,358
EntrestoSacubitril/Valsartan32$22,157
OzempicSemaglutide11$10,081
SavaysaEdoxaban Tosylate12$5,816
Dabigatran EtexilateDabigatran Etexilate Mesylate23$4,879
Metoprolol Succinate218$2,811
Propafenone Hcl41$1,871
Amiodarone Hcl102$1,720
Carvedilol180$1,704
SotalolSotalol Hcl77$1,465
Potassium Chloride87$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$146$564,769632 claims
Johnson & JohnsonXarelto$184$170,793172 claims
Boehringer IngelheimJardiance$31$104,070123 claims
NovartisEntresto$1,026$22,15732 claims
Novo NordiskOzempic$83$10,08111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →